Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MF59-ATIV Immune Responses in Children and Adults
NCT02529904Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Aug 2015
- Primary completion
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Fluzone Trivalent in influenza, sponsored by University of Oxford. Primary endpoint: Early gene transcriptional responses to immunization with MF59-ATIV at 113 days. Started Aug 2015; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02529904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02529904.